Retatrutide Dosing Protocol: Triple Agonist Research

Also known as: LY3437943

metabolic

Research Reference Only

This information is for educational purposes only. Retatrutide is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Retatrutide is a triple hormone receptor agonist (GCGR/GIPR/GLP-1R) developed for obesity and metabolic disorders. It represents a new class of metabolic peptides.

Mechanisms of Action

GLP-1 receptor agonism

GIP receptor agonism

Glucagon receptor agonism

Multi-pathway metabolic regulation

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
Obesity Clinical Trial	clinical trial	12 mg	Weekly	48 weeks	Subcutaneous	clinical trial

Related Studies

Triple hormone receptor agonist retatrutide for obesity - A phase 2 trial

human

2023New England Journal of Medicine

Randomized Controlled Trial

Summary

Retatrutide achieved up to 24.2% weight loss at 48 weeks in obese adults, representing one of the most effective pharmacological interventions for obesity documented.

Limitations

Phase 2 trial; longer-term safety data needed. Gastrointestinal side effects common.

View Original Study

Important Warnings

Safety Considerations

In Phase 3 clinical trials
Not yet FDA approved
Significant weight loss documented